KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

AbbVie (ABBV) Long-Term Deferred Tax (2013)

AbbVie (ABBV) reported Long-Term Deferred Tax of -$582.0 million for Q3 2013.

AbbVie (ABBV) has 1 years of Long-Term Deferred Tax data on file, last reported at -$582.0 million in Q3 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Novartis Ag	107,124,802.25 Bn	107,124,802.25 Bn	-
2	Eli Lilly	969.00 Bn	963.72 Bn	16.22 Bn
3	Johnson & Johnson	539.46 Bn	517.41 Bn	15.96 Bn
4	AbbVie	376.92 Bn	367.57 Bn	10.78 Bn
5	Merck	285.00 Bn	279.35 Bn	12.09 Bn
6	Amgen	177.58 Bn	165.55 Bn	5.87 Bn
7	Gilead Sciences	163.22 Bn	155.50 Bn	5.52 Bn
8	Pfizer	145.86 Bn	133.09 Bn	-1.21 Bn
9	Bristol Myers Squibb	111.90 Bn	101.44 Bn	8.07 Bn
10	Gsk	88.34 Bn	83.66 Bn	-

Historic Data

Download Data 🔒

Date	Value
Sep 30, 2013	-582.00 Mn